Acute Kidney Injury, Hepatorenal Syndrome, Liver Cirrhosis
Conditions
Brief summary
The aim of this study is to investigate i) whether two biomarkers (urine NAG, urinary cystatin C) could be predictive factor in patient with liver cirrhosis, , and ii) whether these biomarkers can predict response of terlipressin.
Detailed description
Acute kidney injury (AKI) in patients with liver cirrhosis is sometimes accompanied by tubular injury which can lead to poor outcome. Current AKI criteria using serum creatinine (Cr) has some limitations to predict reversibility of renal function and discriminate renal parenchymal injury in cirrhotic patients. The aim of this study is to evaluate whether urine biomarkers \[cystatin C, N-acetyl-β-D-Glucosaminidase (NAG)\] can predict survival and response to terlipressin in cirrhotic patients with AKI.
Interventions
None listed
Sponsors
Soonchunhyang University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with liver cirrhosis diagnosed as acute kidney injury or hepatorenal syndrome * Patients who voluntarily agreed to the study
Exclusion criteria
* Patients with active bleeding (eg, varix bleeding) within 7 days * Patients with hepatocellular carcinoma * Patients with hypersensitivity to terlipressin * Patients with anuria * Pregnant and lactating patients * Patients who did not agree with the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | up to 3 years | From date of sample collection until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Transplantation free survival | up to 3 years | From date of sample collection until the date of first liver transplantation or date of death from any cause, whichever came first, assessed up to 3 years |
| Regression of acute kidney injury | up to 1 month | Regression is defined as movement of AKI to a lower stage and decrease of serum creatinine |
| Recurrence of acute kidney injury | up to 1 year | From sample collection day to elevation day of creatinine |
| Progression to chronic kidney disease | 1 year | From sample collection day to progression to CKD |
| Response rate to terlipressin | 1 week | If reduction of creatinine 0.3mg/dL from the baseline |
Countries
South Korea
Contacts
Primary ContactJeong-Ju Yoo, Doctor
Outcome results
None listed